AIM AIM ImmunoTech Inc.

Overview and Growth

Fiscal 2025 results for AIM ImmunoTech Inc. combined $88.00K of revenue with net loss of $13.96M and an operating cash outflow of $10.96M. Revenue of $88.00K sets the scale for evaluating how effectively sales translated into profit and cash during the year. Revenue was 48.2% below fiscal 2024 revenue of $170.00K, marking a top-line contraction. Diluted earnings per share were -$8.62, translating the period’s attributable earnings into the amount reported for each diluted share. A diluted share base of 1.62M links the aggregate earnings figure to diluted EPS and helps frame the per-share comparison. Compared with 560.17K diluted shares in fiscal 2024, the current 1.62M base was 189.0% higher. The company employed $5.78M of total assets, the balance-sheet base supporting its current operating and cash-flow results. Revenue equaled 0.02x of total assets, indicating how much reported top-line activity the company produced relative to its period-end asset base.

Profitability

The company recorded an operating loss of $11.66M after the reported operating expense base. The company ended the period with a net loss of $13.96M, extending the operating result through all remaining items. EBITDA was negative $11.63M, showing a deficit before interest, taxes, depreciation, and amortization. The company reported a pretax loss of $13.96M, before the effect of income taxes. Relative to total assets, the net loss represented 241.4%. The net loss narrowed to $13.96M from $17.32M in fiscal 2024.

Liquidity and Capital Structure

At period end, the $5.78M asset base was financed through $15.56M of liabilities and -$9.78M of equity. With total equity at -$9.78M, the company carried a negative book-capital position, increasing its reliance on liabilities and future earnings. The near-term balance sheet paired $3.29M of current assets with $6.22M of current liabilities at the reporting date. At 0.53x, current liabilities exceeded current assets and placed pressure on the company’s near-term liquidity position. Cash and equivalents totaled $2.98M, identifying the most liquid reported component available within the broader current-asset balance. Measured only with cash and equivalents, coverage of current liabilities was 48.0%, excluding receivables and other current assets. The company carried $4.48M of total debt at period end, which frames its leverage and debt-service burden. Relative to total assets, debt measured 77.4%, showing how much of the asset base was matched by borrowing. Equity equaled -169.2% of assets, showing the shareholder-capital layer within the company’s balance sheet. Liabilities represented 269.2% of total assets, quantifying the liability-funded share of the company’s resource base. The cash-to-assets relationship was 51.6%, comparing reported cash and equivalents with the full positive asset balance. Total assets were 32.8% lower than fiscal 2024 assets of $8.61M, measuring the company’s own balance-sheet change. Cash and equivalents were 75.5% higher than fiscal 2024 cash of $1.70M, showing the year-over-year change in liquid resources.

Cash Flow and Earnings Quality

Cash flow from operations was an outflow of $10.96M, showing that operations absorbed cash during the period. Cash absorbed by operations decreased from $14.89M in fiscal 2024 to $10.96M.

Based on the annual report for the fiscal year ending Dec 31, 2025. Analysis generated Oct 21, 2026.